Q-omics provides the consensus-scored DOC2A profile across patient tissues and cancer cell-line models. DOC2A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DOC2A is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, DOC2A RNA expression shows 21,236 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where DOC2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOC2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOC2A survival associations across molecular data types. DOC2A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOC2A RNA expression–survival associations across cancer types. High DOC2A expression shows unfavorable associations in ACC, CHOL and MESO, but favorable associations in BRCA, SKCM and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DOC2A RNA expression.
This table summarizes DOC2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DOC2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOC2A shows higher tumor expression in KIRC, KIRP, HNSC, BRCA, CHOL and STAD. The KIRC box plot shows higher DOC2A RNA expression in tumor versus normal tissue (log2 FC = +2.296, t-test p < 0.001).
This table shows molecular features associated with DOC2A in patient tissues and cancer cell lines. In patient samples, DOC2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DOC2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
